The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


Novartis reports positive results from two Phase III trials of secukinumab in ankylosing spondylitis.....           Zymeworks, Lilly extend deal for new bi-specific immunotherapies on Azymetric platform.....           Roche to invest $3.2bn in Basel site development.....           Celgene's powerhouse Revlimid gets a little Q3 help from new friends Pomalyst, Otezla.....           Eli Lilly continues downward spiral in Q3 as generics slam Cymbalta, Evista sales.....           Medicines Company sues lawyers for busting Angiomax patent filing deadline.....           Leaping Soliris sales send Alexion's bottom line soaring.....           J&J Innovation taps Texas for its latest biotech startup incubator.....           U.K. watchdogs back Bayer's Xarelto for heart attack patients.....           TWi Biotechnology's AC-201 secures FDA orphan drug status for epidermolysis bullosa.....           TapImmune provides update on PolyStart vaccine platform applicable to cancer and infectious disease.....           Oramed releases positive Phase IIa trial results with oral insulin in type 1 diabetes.....           NICE recommends GSK's skin cancer drug Tafinlar.....           Johnson & Johnson announces major commitment to expedite ebola vaccine development.....           Iroko inks new licensing deal with Landsteiner Scientific to market Zorvolex in Mexico.....           iBio expands exclusive product collaboration with Novici Biotech.....           FDA clears Tonix's IND for TNX-201 to treat episodic tension-type headache.....           EMA grants orphan status for GW Pharmaceuticals' Epidiolex to treat Dravet syndrome.....           Boehringer starts Phase III colorectal cancer trial of nintedanib.....           Roche plots $3.2B overhaul at Basel HQ, joining parade of Big Pharma building projects.....           GSK dealmaking spawns management shake-up, putting Slaoui and Hussain in top slots.....           Spinoff fervor grows: GSK looks at ViiV spinoff and investor tells Amgen to break things up.....           GlaxoSmithKline sets $1.6B in new cost cuts, thanks in part to Advair's U.S. formulary discounts.....           Biogen MS superstar Tecfidera misses estimates; hit with first confirmed PML case.....           New tax rules won't spook Mylan out of Abbott generics buy.....           Cancer survivor's petition pleads with Roche for lower Kadcyla price.....           Synageva begins rolling submission of BLA to FDA for sebelipase alfa to treat LAL Deficiency.....           Immunotech completes negotiations with Uldic to market potential Ebola treatment in Africa.....           NewLink, Genentech ink licensing deal for development of NLG919.....           FDA to review Eisai's sNDA for antiepileptic drug perampanel to treat PGTC seizures.....           Synageva begins rolling submission of BLA to FDA for sebelipase alfa to treat LAL Deficiency.....           CHPA statement on pediatrics study reporting medication errors in children.....           FDA approves Auxilium's Xiaflex to treat Dupuytren's Contracture.....           FDA approves more manufacturing facilities for Halozyme's Hylenex recombinant production.....           Phosplatin starts dosing in Phase I trial of PT-112 for solid tumors.....           Therapix Biosciences signs non-binding agreement to acquire Dekel Pharmaceuticals.....           MabVax Therapeutics nominates HuMab 5B1 as lead clinical development candidate.....           Plandai Biotechnology's technology could prove potent in battling alzheimers disease.....           CHPA statement on pediatrics study reporting medication errors in children.....           Matinas submits IND for MAT9001 to treat severe hypertriglyceridemia.....           Matinas submits IND for MAT9001 to treat severe hypertriglyceridemia.....           Novartis' plaque psoriasis drug candidate AIN457 gets FDA committee recommendation.....           It's back to basics in M&A, and that's a good thing, Actelion CEO says.....           AbbVie faces stumbling blocks after cutting cord on $55B Shire deal.....           Top investor bails on Valeant bid, backing Allergan-Shire combo instead.....           Actavis, Sanofi, Boehringer jockey bids for OTC specialist Omega Pharma.....           Can't stop gambling or shopping? Parkinson's meds may be to blame, JAMA study finds.....           Novartis hopes to rev up Theraflu relaunch with TV celeb Nick Cannon.....           UPDATED: Vertex's Kalydeco scores FDA panel rec in R117H. Are bigger nods next?.....           MedImmune?s Phase I OX40 agonist trial uses AgonOx?s OX40 platform.....           Takeda and Orexigen launch weight management drug Contrave in US.....           FDA accepts to review Merck and Sanofi Pasteur?s BLA for pediatric hexavalent vaccine.....           Apricus expands development pipeline with the in-licensing of US rights for fispemifene, a phase 2b ready asset, from forendo pharma targeting urological conditions in men.....           Apricus expands development pipeline with in-licensing of US rights for fispemifene.....           Cerus submits compassionate use IDE supplement for INTERCEPT Blood System treatment of ebola convalescent plasma.....           Cannabics Pharmaceuticals receives Cannabinoid R&D lab certification in Israel.....           Revalesio's RNS60 shows promise in treating Alzheimer's disease and other dementias.....           Enanta Pharmaceuticals provides update on its collaboration agreement with AbbVie.....           Baxter introduces Hyqvia in US to treat primary immunodeficiency.....           Genervon reports Phase IIa trial results of GM6 drug in ALS and PD.....           UPDATED: Thumbing its nose at critics, Valeant touts Q3 growth, hikes forecasts.....           Addiction-riddled Kentucky out for blood in $1B suit against OxyContin-maker Purdue.....           Shire CFO jumps ship as post-AbbVie deal talk heats up.....           PhRMA hits back at payers with new site highlighting coverage shortfalls.....           Regeneron's Eylea bests Lucentis, Avastin in diabetic eye disease, NIH study finds.....           Will Pfizer rebid for AstraZeneca? Keep an eye on U.S. midterm election for clues.....           Pharmacyclics' Imbruvica gets European approval to treat two blood cancers.....           DKSH to offer market expansion services for Roche's products across Asia.....           Horizon Pharma acquires US rights to Pennsaid 2% from Nuvo Research.....           China Biologic gets approval to manufacture human prothrombin complex concentrate at Shandong Taibang facility.....           Amgen files Lawsuit against Sanofi and Regeneron for patent infringement.....           GSK update on current development status of the GSK/NIH Ebola vaccine candidate.....           EYLEA injection shows better gains in visual acuity than both bevacizumab and ranibizumab in NIH-sponsored DME study.....           Amicus Therapeutics reports positive phase III data from fabry monotherapy study 011.....           EMA grants orphan drug status for Immunomedics' isactuzumab govitecan for pancreatic cancer.....           Immune Design, Sanofi Pasteur to develop herpes simplex virus therapy.....           Aduro expands deal with Janssen to develop product candidates for lung cancer.....           OctreoPharm's OPS202 receives FDA orphan drug status for neuroendocrine tumors.....           Actavis seeks FDA approval to market Methylphenidate Hydrochloride 5mg/mL.....           Health Canada issues notice of compliance for Gilead hepatitis C drug Harvoni.....           UPDATED: FDA panel say Pfizer's Chantix should continue to wear a 'black box' label.....           Lilly will close Puerto Rico plant, affecting 100 workers.....           AbbVie's $1.635B breakup fee to Shire, if paid, will run third highest ever.....           Baxter prepping for HyQvia launch with spinoff's success on the line.....           Bristol-Myers catches a break as Indian agency delays Sprycel patent decision.....           Kalydeco in R117H patients? As AdComm nears, Vertex drug faces doubts.....           AstraZeneca, Cambridge University collaborate to research on neurodegenerative diseases.....           Ranbaxy agrees to pay $39.75m to settle Texas Medicaid litigation.....           Noven files patent infringement lawsuit against Actavis.....           Ampio reports results of multiple intra-articular injections (MI) study of Ampion in patients with osteoarthritis of the knee.....           Bone Biologics completes merger with AFH Acquisition X.....           Batu Biologics gets license from California University for cancer drug.....           Nuvilex gets worldwide license for insulin-producing cells from University of Technology for use in developing diabetes treatment.....           Portal Instruments completes landmark $11m series A financing for new drug delivery platform.....           NeuroSigma, US Veterans Administration (VA) enter into cooperative research and development agreement.....           Mariel Therapeutics announces issuance of two US patents for use BMP-7 in OA and CKD.....           InVivo Therapeutics announces first subject enrolled in pilot spinal cord injury trial.....           Orgenesis receives patent for potential cure for type 1 diabetes.....           Prima announces immutep's IMP321 patent application receives Australian notice of allowance.....           Selecta, JDRF and Sanofi to develop SVP immunotherapy for type 1 diabetes.....           MorphoSys acquires Lanthio's lanthipeptide technology.....           FDA approves Navidea?s lymphoseek for lymphatic mapping in solid tumors.....           Once again, Roche breast cancer franchise shines, sending Q3 drug sales up 4%.....           AbbVie calls it quits on $55B Shire takeover.....           Hospira says saline recall will not make shortage worse.....           Matchmaking for Shire and AbbVie already? Try Allergan (of course) and Pfizer.....           Same-day approvals send Roche, Boehringer to IPF market battle.....           If Teva wanted a clear sign from Supreme Court on Copaxone, no such luck.....           FDA approves Boehringer's Ofev to treat idiopathic pulmonary fibrosis.....           Infinity reports topline data from phase 2a exploratory study of duvelisib in asthma patients.....           Genentech gets FDA approval for Esbriet to treat idiopathic pulmonary fibrosis.....           ActoGeniX reports positive results from Phase I trial of AG014 to treat inflammatory bowel disease.....           Vaxart?s tablet vaccine for H1N1 influenza generates protective immunity equivalent to injectable in Phase I clinical study.....           Axxess Pharma launches new TapouT Turbo Blend protein powder.....           Breckenridge launches Mefenamic acid 250mg capsules.....           FDA grants priority review designation for Eisai's Lenvatinib to treat advanced thyroid cancer.....           Sucampo extends license, collaboration agreement with Takeda for Amitiza.....           AbbVie-Shire deal in jeopardy, but not necessarily dead.....           GSK starts unloading older meds by region, with $3B portfolio up for grabs.....           Former Merck staffer charged in insider trading case.....           FDA grants a combo-med exclusivity wish. Why is that a problem?.....           Déjà vu for Celgene as NICE says 'no' to myeloma drug Imnovid.....           Gilead, Allergan, Novo and Valeant chiefs make the list of world's top 10.....           New Ebola cases may reach 10,000 per week by year end: WHO.....           MissionPoint Health Partners and Second Harvest Food Bank of middle tennessee create partnership.....           Macular Health announces release of MacuStrip.....           Encore Consumer Capital announces sale of Isopure to Glanbia.....           RSS NEWSFEED....
APS PharmSci 2014
Declared Huge Success
 
Please browse some of the messages below from the Conference Science Chair, APS Chair and Chief Scientist regarding their positive experiences at the recent APS PharmSci Conference.

READ MORE
Message from Linda Hakes-Conference Science Chair
It was a tremendous honour to be asked to be the Conference Science Chair for PharmSci 2014 but also more than a little daunting. The previous holders of the position had helped to establish the meeting as the premier UK conference on the pharmaceutical sciences and I didn’t want to let the side down.











READ MORE
Message from Bill Dawson, Chair APS
PharmSci 2014 was a huge success. Attendance was excellent, content was good and participants were lively and engaged. My lasting memory of the conference this year was the quality and enthusiasm of the poster presenters. They were professional and their material was in many cases really novel and thought provoking. Those selected for podium presentations did really well, particularly those for whom it was their first occasion. I well remember my first communication which seemed a blur I was so nervous. I still have no idea whether I did well or not.












READ MORE
Message from Claire Thompson-APS Chief Scientist
The APS PharmSci conference was, once again, a huge success. Gathering more than 550 scientists from industry, academia and regulatory agencies, the conference showcased innovation in research, ranging from graphene to regenerative medicine and biopharmaceutics to theranostics.












Keep your eye open for more reports, photos, feedback from the conference to follow over the coming weeks.
 
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences is the professional body for the Pharmaceutical Sciences in United Kingdom. A Pharmaceutical Scientist is an individual who contributes to bringing a new drug from concept through to a medicinal product. This includes, but is not exclusive to, individuals in academia, industry, regulation, clinical research and manufacturing.

The mission of the Academy of Pharmaceutical Sciences is to champion innovation and opportunity in Pharmaceutical Sciences for the delivery of medicines.

In order to achieve this mission, our aims are to:

  • Promote the Pharmaceutical Sciences to stakeholders to facilitate understanding and achieve engagement
  • Share learning, drive collaboration, partnership and innovation
  • Deliver insights into industry and academic roles for aspiring scientists

Latest News
The European Paediatric Formulation Initiative (EuPFI) paediatric biopharmaceutics survey
WEDNESDAY, 22 OCTOBER 2014
The EuPFI (European Paediatric Formulation Initiative www.eupfi.org) are looking to gather the views of biopharmaceuics scientists on the development of a paediatric biopharmaceutics classification system.. If you are an individual working in the area of biopharmaceutics, we would really appreciate your time in completing this short survey. Note that we would like individuals to complete this based on their own opinions and not necessarily those of their employer. Feel free to share this with others working in this area.. xhttps://www.survey.bris.ac.uk/bham/eupfi-biopharm-bcs . We anticipated that this will take 10-15 minutes and we plan to share our findings via the EuPFI but please leave your contact details within the questionnaire if you would like a direct mail regarding the output.. With many thanks for your time. The EuPFI Biopharmaceutics workstream.
Information Webinar ITT Modular Masters Formulation Consortium
TUESDAY, 7 OCTOBER 2014
Interested in Delivering the Modular Masters in Formulation Science and Technology? Information Webinars for Providers 10th and 13th October. You may have already heard about the Science Industry Partnership (SIP) and the innovative new Modular Masters Programme in Formulation Science and Technology. If not, you will find further details on the SIP website: xhttp://www.scienceindustrypartnership.com/modular-masters/.. The process to select the provider or provider consortium which will deliver the full programme in collaboration with the SIP has now begun. There are opportunities for Higher Education Institutions (HEIs) as well as private sector and other educational providers to become involved. So if you are interested in finding out how you could become part of this exciting new programme then register now for one of our short briefing webinars to be held on Friday 10th October at 11.00 AM or Monday 13th October at 12.30 PM.. To register to attend, simply e-mail info@iformulate.biz with your full contact details and preferred webinar date. We will send webinar joining details to registrants ahead of time.. We expect the formal application process to open at the end of October and close at the end of November. Final selection of the provider or provider consortium will be made in early January 2015.. We will also be helping provider consortiums to form by sharing contact details and areas of expertise of interested parties. If you would like your details to be shared in this way, please provide (by e-mail to info@iformulate.biz) a short description of topics, expertise and existing or planned relevant educational provision. If you are considering leading a consortium, you may also wish to indicate in which areas you require partners to fill any gaps in provision.. We look forward to speaking with you at one of the webinars... Tina Roberts Higher Education Development Manager Cogent Sector Skills Council Unit 5 Mandarin Court Centre Park Warrington WA1 1GG. Tel: 01925 515200 x301 Mobile: 07715014099 Fax: 01925 515240 Email: tina.roberts@cogent-ssc.com Web: www.cogent-ssc.com.
Unique leadership event for women in healthcare science leadership
TUESDAY, 16 SEPTEMBER 2014
The Academy of Pharmaceutical Sciences (APS) and Royal Pharmaceutical Society (RPS) are organising a symposium on the 7 October 2014 for women in healthcare science leadership.. The organisers have put together a panel of leading professionals to help women develop their careers and includes eminent speakers from across clinical pharmacy, academic research and industry. The event is attracting a wide audience of individuals involved in leadership in the healthcare science and we would love to see you there.. . Are you looking to take the next step in your career? Are you ready to set new challenges and enhance your leadership skills?. Join us to hear from inspiring leaders in academic research, clinical pharmacy, and industry.. Helen Gordon, Chief Executive, Royal Pharmaceutical Society, says: “Our Women in healthcare science leadership symposium is a new event, developed to support women in existing or aspiring leadership roles. Attending will provide you with the perfect opportunity to challenge what you know about yourself and develop practical skills that will support your career. I for one am looking forward to hearing from our great line-up of speakers, who I’m sure will inspire and motivate you to excel and lead others in your field.”. The symposium has great networking potential with speakers from across clinical pharmacy, academic research and life sciences including:. Cathy Mooney MRPharmS, Deputy Director of Quality and Safety, University College London Hospitals NHS Foundation Trust Harriet Fear, CEO, One Nucleus Helena Morrissey CBE, CEO, Newton and Founder 30% Club Philippa Roberts MRPharmS, Director of Pharmacy and Risk Management, Wirral University Teaching Hospital NHS Foundation Trust Themes include leadership, innovation and entrepreneurship. During the day, you will:. Learn how to develop your leadership skills and successfully drive your career forwards Identify the successes and challenges for women in the workplace Discuss real life experiences with leading healthcare practitioners Examine the benefits of diversity in the workplace Learn how to overcome the barriers (both real and perceived) to becoming a leader Learn how to influence at the most senior level and to build networks. There will also be a Q&A session, giving you the unique opportunity to ask specific questions relating to your career.. We aim to provide you with the skills and confidence to successfully drive your career forward. Don't miss out: view the full programme and register today.. http://www.rpharms.com/conferences/women-in-healthcare-science-leadership -symposium.asputm_medium=email&utm_source=Royal+Pharmaceutical+Society &utm_campaign=4695578_Women+in+healthcare+event+-+generic&dm_i=EQ,2S N4Q,G415KU,A5V2J,1.
Award Winners at APS PharmSci 2014
WEDNESDAY, 3 SEPTEMBER 2014
APS Invited lecture at PharmSci Conference 2014 on Monday September 8th from 13.45-14.35. . The APS are pleased to announce that Abdul Basit will deliver the APS lecture this year entitled Gut instincts: explorations in intestinal physiology and drug delivery. The APS lecture award is sponsored by AstraZeneca and is awarded to nominated members of APS who have made outstanding scientific contribution in their work and are ambassadors in their area with an international reputation.. Abdul Basit holds the position of Professor of Pharmaceutics at the University College London (UCL) School of Pharmacy. He is also a Visiting Professor in the Faculty of Chemical and Pharmaceutical Sciences at the University of Chile. Furthermore, he holds an Honorary Research Fellow in Gastroenterology at the Wingate Institute of Neurogastroenterology, Queen Mary College, University of London.. Abdul's research sits at the interface between pharmaceutical science and gastroenterology, forging links between basic science and clinical outcomes. He leads a large and multi-disciplinary research group, and the goal of his work is to further the understanding of gastrointestinal physiology by fundamental research. So far, this knowledge has been translated into the design of new technologies and improved disease treatments, many of which are currently in late stage clinical trials.. Abdul is also the only non-North American scientist to receive the Young Investigator Award in Pharmaceutics and Pharmaceutical Technology from the American Association of Pharmaceutical Scientists (AAPS). Moreover, he is the founder and director of two spin-out companies, and serves on the scientific advisory boards of pharmaceutical companies, healthcare organisations and charitable bodies, including the Clinton Health Access Initiative (CHAI).. . Winner of the 2014 Royal Pharmaceutical Society Science Award announced. Professor Benjamin J. Whalley has been announced as winner of the 2014 Royal Pharmaceutical Society’s prestigious Science Award. The award will be presented at the APS PhamSci 2014 conference at the University of Hertfordshire, when Professor Whalley will deliver a plenary lecture on The therapeutic value of non-psychoactive components of cannabis in epilepsy: from lab to clinic.. The lecture will take place on Tuesday 9th September at 1335.. . . . The RPS Science Award has a long history with previous winners invariably going on to make significant contributions in the field of pharmaceutical science. The award is presented to a pharmaceutical scientist with no more than 10 years’ experience at post-doctoral level who has a proven record of independent research and published work that shows outstanding promise.. Professor Benjamin J. Whalley studies neuronal processes that underlie complex physiological functions, specifically neuronal hyperexcitability states and their consequential disorders (e.g. epilepsy, ataxia and dystonias). As a registered pharmacist (1992-present), Professor Whalley’s research in this area has primarily focused upon preclinical drug development in epilepsy. Here, he has primarily employed electrophysiological approaches with a variety of in vitro models of epileptiform activity and a number of in vivo rodent models of seizure and epilepsy.. He has used these approaches to examine the cellular and neuronal network mechanisms that underlie the effects of anti-epileptic drugs (AEDs) that are in clinical use or currently in clinical trials (e.g. levetiracetam (UCB Pharmaceuticals), carisbamate and topiramate (RW Johnson)). More recently, his work has examined the effects of several non-psychoactive components of marijuana (‘phytocannabinoids’) upon hyperexcitability states. Here, he has demonstrated that several of these phytocannabinoids exert significant anti-epileptic effects and, since 2008, has worked with GW Pharmaceuticals and Otsuka Pharmaceuticals to develop these drugs to the point of translation to human clinical trials. This work has yielded 4 international patents and, in 2013, initiation of Phase 1 human clinical trials for one drug (cannabidavarin) and Phase 2 human clinical trials for another (cannabidiol) in drug resistant, pediatric epilepsies. Early efficacy data from these trials has shown that cannabidiol has beneficial effects upon seizures in otherwise treatment-resistant paediatric epilepsy patients.. Prof. Whalley’s expertise in this area is further reflected in his role as an expert witness in criminal trials involving cannabis, his invited authorship of The American Herbal Pharmacopeia’s monograph on Cannabis and Epilepsy and recent appointment to the UK Advisory Council on the Misuse of Drugs. His work with non-psychoactive phytocannabinoids has also included work with colleagues which has revealed cannabinoid effects upon appetite and feeding behaviours, anti-ataxic mechanisms of action in the cerebellum and ongoing studies of the effect of these compounds in cachexic states.. A significant component of Prof. Whalley’s research has also been the development of experimental platforms which combine biological (e.g. neuronal cell culture, acute brain slices) and machine (e.g. robotic) systems to produce brain-machine interfaces (BMI) as tools for investigating the cellular correlates of complex CNS functions, including stem cell-based approaches. This research has thus far culminated in development of the first bioelectrically functional, 3D human neuronal network from stem cells, using biocompatible scaffolds; work featured in recent BBC science programming. This BMI research has formed part of presentations to the UK Cabinet Office and the US Senate, features in New Scientist, The Lancet, national broadsheets, national and international television and radio, an exhibit at the London Science Museum.. Both of the above research strands were chosen to act as two of the three Research Excellence Framework (REF) Impact Case Studies submitted by the Reading School of Pharmacy. Prof. Whalley has won ~£6M grant funding since taking up his first independent academic position in 2005 and his current grant funding supports a research group of 2 PDRAs and 9 PhD students. He has successfully supervised 13 PhD students to completion (100% success rate)..
Follow us
 
Upcoming Events
APS Drying Technologies for Biopharmaceuticals
28 January 2015
APS Industrial Insights 2015
16 - 17 April 2015
APS PharmSci 2015
7 - 9 September 2015
APS Pharmaceutical Photostability 2015
5 - 7 October 2015
APS Material Science
13 - 14 April 2015
Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.